Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules
NCT07340177Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Xiaojin and Neixiao Luoli Pill in thyroid nodule (3 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Percentage Change in Thyroid Nodule Volume at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
XiaojinNeixiao Luoli Pill
03
Conditions
thyroid nodule
Beyond the preview
Go deeper on NCT07340177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340177.